Getting to Complete Response With Less Toxicity in HER2-Positive Early Breast Cancer

Getting to Complete Response With Less Toxicity in HER2-Positive Early Breast Cancer

(MedPage Today) -- In the DESTINY-Breast11 (DB11) trial, trastuzumab deruxtecan (T-DXd, Enhertu), followed by the taxane paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta) in combination (THP), improved pathologic complete response...

KN026/KN046 Combo Yields Durable Responses in HER2+ mBC

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

Targeted Nanozyme Therapy For HER2 Cancer - Data Intelligence

Researchers have developed a new nanomaterial platform that combines nanozymes with antibody targeting to improve the precision and effectiveness of treatment in HER2-positive cancer models. Their goal is to block transcriptional processes that support tumor growth and spread by disrupting gene expression pathways central to cancer progression. Image Credit: alicancomertpay/Shutterstock.com Background HER2 (human epidermal growth factor receptor…